“The simplSEQ workflow offers many workflow advantages over other methods of cell-free DNA extraction especially speed, simplicity, reproducibility, which are
Blog
Company Filed Second Patent Application to Extend Core Technology Applications
Murrieta Genomics is pleased to announce that U.S. Patent and Trademark
Murrieta Genomics, the launch pad for genomic sequencing startups, is pleased to announce that simplSEQ, an incubator company and subsidiary,
“Our first product is a kit for the purification and isolation of nucleic acids from plasma that we believe will
Press Releases
“The simplSEQ workflow offers many workflow advantages over other methods of cell-free DNA extraction especially speed, simplicity, reproducibility, which are
Company Filed Second Patent Application to Extend Core Technology Applications
Murrieta Genomics is pleased to announce that U.S. Patent and Trademark
Murrieta Genomics, the launch pad for genomic sequencing startups, is pleased to announce that simplSEQ, an incubator company and subsidiary,
“Our first product is a kit for the purification and isolation of nucleic acids from plasma that we believe will
Blog
“The simplSEQ workflow offers many workflow advantages over other methods of cell-free DNA extraction especially speed, simplicity, reproducibility, which are
Company Filed Second Patent Application to Extend Core Technology Applications
Murrieta Genomics is pleased to announce that U.S. Patent and Trademark
Murrieta Genomics, the launch pad for genomic sequencing startups, is pleased to announce that simplSEQ, an incubator company and subsidiary,
“Our first product is a kit for the purification and isolation of nucleic acids from plasma that we believe will
Press Releases
“The simplSEQ workflow offers many workflow advantages over other methods of cell-free DNA extraction especially speed, simplicity, reproducibility, which are
Company Filed Second Patent Application to Extend Core Technology Applications
Murrieta Genomics is pleased to announce that U.S. Patent and Trademark
Murrieta Genomics, the launch pad for genomic sequencing startups, is pleased to announce that simplSEQ, an incubator company and subsidiary,
“Our first product is a kit for the purification and isolation of nucleic acids from plasma that we believe will
Recent News
An article in Science magazine on December 13 explains how genomic sequencing was able to track the latest E. coli
John Powers, co-founder and President of Murrieta Genomics, LLC, the Southern California genomic sequencing business incubator, is pleased to announce
During our grand opening in August, we took the time to interview many of our partners and supporters. The interviews
Researchers at the Broad Institute of MIT and Harvard, Koch Institute at MIT, Dana-Farber Cancer Institute, and Massachusetts General Hospital
Media Resources
On Friday, January 29th 2021 an article about Murrieta Genomics and our wholly owned subsidiary, SimplSEQ, was published by GenomeWeb.
The RuleOut team has created a novel approach that can exponentially increase COVID-19 testing capacity.
Murrieta Genomics and SimplSeq to Participate in Life Science Nation's Digital RESI Partnering Event
Life Science Nation provides an incredibly important service to early stage life science companies by connecting them with products, services
John Powers, President of Murrieta Genomics and CEO of SimplSeq, our wholly owned subsidiary, was interviewed recently on Beyone with